<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1993-07-01" modified="2017-12-20" version="196">
<accession>P31751</accession>
<accession>B2RBD8</accession>
<accession>Q05BV0</accession>
<accession>Q0VAN0</accession>
<accession>Q0VAN1</accession>
<accession>Q68GC0</accession>
<name>AKT2_HUMAN</name>
<protein>
<recommendedName>
<fullName>RAC-beta serine/threonine-protein kinase</fullName>
<ecNumber>2.7.11.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Protein kinase Akt-2</fullName>
</alternativeName>
<alternativeName>
<fullName>Protein kinase B beta</fullName>
<shortName>PKB beta</shortName>
</alternativeName>
<alternativeName>
<fullName>RAC-PK-beta</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary">AKT2</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="Cell Regul." volume="2" first="1001" last="1009">
<title>Molecular cloning of a second form of rac protein kinase.</title>
<authorList>
<person name="Jones P.F."/>
<person name="Jakubowicz T."/>
<person name="Hemmings B.A."/>
</authorList>
<dbReference type="PubMed" id="1801921"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Epithelium</tissue>
</source>
</reference>
<reference key="2">
<citation type="journal article" date="1992" name="Proc. Natl. Acad. Sci. U.S.A." volume="89" first="9267" last="9271">
<title>AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.</title>
<authorList>
<person name="Cheng J.Q."/>
<person name="Godwin A.K."/>
<person name="Bellacosa A."/>
<person name="Taguchi T."/>
<person name="Franke T.F."/>
<person name="Hamilton T.C."/>
<person name="Tsichlis P.N."/>
<person name="Testa J.R."/>
</authorList>
<dbReference type="PubMed" id="1409633"/>
<dbReference type="DOI" id="10.1073/pnas.89.19.9267"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
</reference>
<reference key="3">
<citation type="journal article" date="2004" name="Nat. Genet." volume="36" first="40" last="45">
<title>Complete sequencing and characterization of 21,243 full-length human cDNAs.</title>
<authorList>
<person name="Ota T."/>
<person name="Suzuki Y."/>
<person name="Nishikawa T."/>
<person name="Otsuki T."/>
<person name="Sugiyama T."/>
<person name="Irie R."/>
<person name="Wakamatsu A."/>
<person name="Hayashi K."/>
<person name="Sato H."/>
<person name="Nagai K."/>
<person name="Kimura K."/>
<person name="Makita H."/>
<person name="Sekine M."/>
<person name="Obayashi M."/>
<person name="Nishi T."/>
<person name="Shibahara T."/>
<person name="Tanaka T."/>
<person name="Ishii S."/>
<person name="Yamamoto J."/>
<person name="Saito K."/>
<person name="Kawai Y."/>
<person name="Isono Y."/>
<person name="Nakamura Y."/>
<person name="Nagahari K."/>
<person name="Murakami K."/>
<person name="Yasuda T."/>
<person name="Iwayanagi T."/>
<person name="Wagatsuma M."/>
<person name="Shiratori A."/>
<person name="Sudo H."/>
<person name="Hosoiri T."/>
<person name="Kaku Y."/>
<person name="Kodaira H."/>
<person name="Kondo H."/>
<person name="Sugawara M."/>
<person name="Takahashi M."/>
<person name="Kanda K."/>
<person name="Yokoi T."/>
<person name="Furuya T."/>
<person name="Kikkawa E."/>
<person name="Omura Y."/>
<person name="Abe K."/>
<person name="Kamihara K."/>
<person name="Katsuta N."/>
<person name="Sato K."/>
<person name="Tanikawa M."/>
<person name="Yamazaki M."/>
<person name="Ninomiya K."/>
<person name="Ishibashi T."/>
<person name="Yamashita H."/>
<person name="Murakawa K."/>
<person name="Fujimori K."/>
<person name="Tanai H."/>
<person name="Kimata M."/>
<person name="Watanabe M."/>
<person name="Hiraoka S."/>
<person name="Chiba Y."/>
<person name="Ishida S."/>
<person name="Ono Y."/>
<person name="Takiguchi S."/>
<person name="Watanabe S."/>
<person name="Yosida M."/>
<person name="Hotuta T."/>
<person name="Kusano J."/>
<person name="Kanehori K."/>
<person name="Takahashi-Fujii A."/>
<person name="Hara H."/>
<person name="Tanase T.-O."/>
<person name="Nomura Y."/>
<person name="Togiya S."/>
<person name="Komai F."/>
<person name="Hara R."/>
<person name="Takeuchi K."/>
<person name="Arita M."/>
<person name="Imose N."/>
<person name="Musashino K."/>
<person name="Yuuki H."/>
<person name="Oshima A."/>
<person name="Sasaki N."/>
<person name="Aotsuka S."/>
<person name="Yoshikawa Y."/>
<person name="Matsunawa H."/>
<person name="Ichihara T."/>
<person name="Shiohata N."/>
<person name="Sano S."/>
<person name="Moriya S."/>
<person name="Momiyama H."/>
<person name="Satoh N."/>
<person name="Takami S."/>
<person name="Terashima Y."/>
<person name="Suzuki O."/>
<person name="Nakagawa S."/>
<person name="Senoh A."/>
<person name="Mizoguchi H."/>
<person name="Goto Y."/>
<person name="Shimizu F."/>
<person name="Wakebe H."/>
<person name="Hishigaki H."/>
<person name="Watanabe T."/>
<person name="Sugiyama A."/>
<person name="Takemoto M."/>
<person name="Kawakami B."/>
<person name="Yamazaki M."/>
<person name="Watanabe K."/>
<person name="Kumagai A."/>
<person name="Itakura S."/>
<person name="Fukuzumi Y."/>
<person name="Fujimori Y."/>
<person name="Komiyama M."/>
<person name="Tashiro H."/>
<person name="Tanigami A."/>
<person name="Fujiwara T."/>
<person name="Ono T."/>
<person name="Yamada K."/>
<person name="Fujii Y."/>
<person name="Ozaki K."/>
<person name="Hirao M."/>
<person name="Ohmori Y."/>
<person name="Kawabata A."/>
<person name="Hikiji T."/>
<person name="Kobatake N."/>
<person name="Inagaki H."/>
<person name="Ikema Y."/>
<person name="Okamoto S."/>
<person name="Okitani R."/>
<person name="Kawakami T."/>
<person name="Noguchi S."/>
<person name="Itoh T."/>
<person name="Shigeta K."/>
<person name="Senba T."/>
<person name="Matsumura K."/>
<person name="Nakajima Y."/>
<person name="Mizuno T."/>
<person name="Morinaga M."/>
<person name="Sasaki M."/>
<person name="Togashi T."/>
<person name="Oyama M."/>
<person name="Hata H."/>
<person name="Watanabe M."/>
<person name="Komatsu T."/>
<person name="Mizushima-Sugano J."/>
<person name="Satoh T."/>
<person name="Shirai Y."/>
<person name="Takahashi Y."/>
<person name="Nakagawa K."/>
<person name="Okumura K."/>
<person name="Nagase T."/>
<person name="Nomura N."/>
<person name="Kikuchi H."/>
<person name="Masuho Y."/>
<person name="Yamashita R."/>
<person name="Nakai K."/>
<person name="Yada T."/>
<person name="Nakamura Y."/>
<person name="Ohara O."/>
<person name="Isogai T."/>
<person name="Sugano S."/>
</authorList>
<dbReference type="PubMed" id="14702039"/>
<dbReference type="DOI" id="10.1038/ng1285"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="4">
<citation type="journal article" date="2004" name="Nature" volume="428" first="529" last="535">
<title>The DNA sequence and biology of human chromosome 19.</title>
<authorList>
<person name="Grimwood J."/>
<person name="Gordon L.A."/>
<person name="Olsen A.S."/>
<person name="Terry A."/>
<person name="Schmutz J."/>
<person name="Lamerdin J.E."/>
<person name="Hellsten U."/>
<person name="Goodstein D."/>
<person name="Couronne O."/>
<person name="Tran-Gyamfi M."/>
<person name="Aerts A."/>
<person name="Altherr M."/>
<person name="Ashworth L."/>
<person name="Bajorek E."/>
<person name="Black S."/>
<person name="Branscomb E."/>
<person name="Caenepeel S."/>
<person name="Carrano A.V."/>
<person name="Caoile C."/>
<person name="Chan Y.M."/>
<person name="Christensen M."/>
<person name="Cleland C.A."/>
<person name="Copeland A."/>
<person name="Dalin E."/>
<person name="Dehal P."/>
<person name="Denys M."/>
<person name="Detter J.C."/>
<person name="Escobar J."/>
<person name="Flowers D."/>
<person name="Fotopulos D."/>
<person name="Garcia C."/>
<person name="Georgescu A.M."/>
<person name="Glavina T."/>
<person name="Gomez M."/>
<person name="Gonzales E."/>
<person name="Groza M."/>
<person name="Hammon N."/>
<person name="Hawkins T."/>
<person name="Haydu L."/>
<person name="Ho I."/>
<person name="Huang W."/>
<person name="Israni S."/>
<person name="Jett J."/>
<person name="Kadner K."/>
<person name="Kimball H."/>
<person name="Kobayashi A."/>
<person name="Larionov V."/>
<person name="Leem S.-H."/>
<person name="Lopez F."/>
<person name="Lou Y."/>
<person name="Lowry S."/>
<person name="Malfatti S."/>
<person name="Martinez D."/>
<person name="McCready P.M."/>
<person name="Medina C."/>
<person name="Morgan J."/>
<person name="Nelson K."/>
<person name="Nolan M."/>
<person name="Ovcharenko I."/>
<person name="Pitluck S."/>
<person name="Pollard M."/>
<person name="Popkie A.P."/>
<person name="Predki P."/>
<person name="Quan G."/>
<person name="Ramirez L."/>
<person name="Rash S."/>
<person name="Retterer J."/>
<person name="Rodriguez A."/>
<person name="Rogers S."/>
<person name="Salamov A."/>
<person name="Salazar A."/>
<person name="She X."/>
<person name="Smith D."/>
<person name="Slezak T."/>
<person name="Solovyev V."/>
<person name="Thayer N."/>
<person name="Tice H."/>
<person name="Tsai M."/>
<person name="Ustaszewska A."/>
<person name="Vo N."/>
<person name="Wagner M."/>
<person name="Wheeler J."/>
<person name="Wu K."/>
<person name="Xie G."/>
<person name="Yang J."/>
<person name="Dubchak I."/>
<person name="Furey T.S."/>
<person name="DeJong P."/>
<person name="Dickson M."/>
<person name="Gordon D."/>
<person name="Eichler E.E."/>
<person name="Pennacchio L.A."/>
<person name="Richardson P."/>
<person name="Stubbs L."/>
<person name="Rokhsar D.S."/>
<person name="Myers R.M."/>
<person name="Rubin E.M."/>
<person name="Lucas S.M."/>
</authorList>
<dbReference type="PubMed" id="15057824"/>
<dbReference type="DOI" id="10.1038/nature02399"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2)</scope>
<source>
<tissue>Lymph</tissue>
</source>
</reference>
<reference key="6">
<citation type="submission" date="2004-08" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 237-277</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1998" name="Biochem. J." volume="331" first="299" last="308">
<title>Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha.</title>
<authorList>
<person name="Walker K.S."/>
<person name="Deak M."/>
<person name="Paterson A."/>
<person name="Hudson K."/>
<person name="Cohen P."/>
<person name="Alessi D.R."/>
</authorList>
<dbReference type="PubMed" id="9512493"/>
<dbReference type="DOI" id="10.1042/bj3310299"/>
</citation>
<scope>CHARACTERIZATION</scope>
<scope>PHOSPHORYLATION AT THR-309 BY PDPK1</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2000" name="Mol. Cell" volume="6" first="395" last="407">
<title>The protooncogene TCL1 is an Akt kinase coactivator.</title>
<authorList>
<person name="Laine J."/>
<person name="Kuenstle G."/>
<person name="Obata T."/>
<person name="Sha M."/>
<person name="Noguchi M."/>
</authorList>
<dbReference type="PubMed" id="10983986"/>
<dbReference type="DOI" id="10.1016/S1097-2765(00)00039-3"/>
</citation>
<scope>INTERACTION WITH MTCP1; TCL1A AND TCL1B</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2005" name="Biochim. Biophys. Acta" volume="1725" first="340" last="347">
<title>Activation of a GST-tagged AKT2/PKBbeta.</title>
<authorList>
<person name="Baer K."/>
<person name="Lisinski I."/>
<person name="Gompert M."/>
<person name="Stuhlmann D."/>
<person name="Schmolz K."/>
<person name="Klein H.W."/>
<person name="Al-Hasani H."/>
</authorList>
<dbReference type="PubMed" id="15890450"/>
<dbReference type="DOI" id="10.1016/j.bbagen.2005.04.002"/>
</citation>
<scope>MUTAGENESIS OF THR-309 AND SER-474</scope>
<scope>PHOSPHORYLATION AT THR-309 AND SER-474</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2006" name="Biochem. J." volume="399" first="9" last="20">
<title>A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.</title>
<authorList>
<person name="Fritzius T."/>
<person name="Burkard G."/>
<person name="Haas E."/>
<person name="Heinrich J."/>
<person name="Schweneker M."/>
<person name="Bosse M."/>
<person name="Zimmermann S."/>
<person name="Frey A.D."/>
<person name="Caelers A."/>
<person name="Bachmann A.S."/>
<person name="Moelling K."/>
</authorList>
<dbReference type="PubMed" id="16792529"/>
<dbReference type="DOI" id="10.1042/BJ20060511"/>
</citation>
<scope>INTERACTION WITH WDFY2</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="13949" last="13956">
<title>Kinetic mechanism of AKT/PKB enzyme family.</title>
<authorList>
<person name="Zhang X."/>
<person name="Zhang S."/>
<person name="Yamane H."/>
<person name="Wahl R."/>
<person name="Ali A."/>
<person name="Lofgren J.A."/>
<person name="Kendall R.L."/>
</authorList>
<dbReference type="PubMed" id="16540465"/>
<dbReference type="DOI" id="10.1074/jbc.M601384200"/>
</citation>
<scope>BIOPHYSICOCHEMICAL PROPERTIES</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2008" name="J. Cell. Physiol." volume="214" first="158" last="165">
<title>Akt2 is implicated in skeletal muscle differentiation and specifically binds Prohibitin2/REA.</title>
<authorList>
<person name="Heron-Milhavet L."/>
<person name="Mamaeva D."/>
<person name="Rochat A."/>
<person name="Lamb N.J."/>
<person name="Fernandez A."/>
</authorList>
<dbReference type="PubMed" id="17565718"/>
<dbReference type="DOI" id="10.1002/jcp.21177"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH PBH2</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="14">
<citation type="journal article" date="2009" name="Dev. Cell" volume="17" first="800" last="810">
<title>The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt.</title>
<authorList>
<person name="Suizu F."/>
<person name="Hiramuki Y."/>
<person name="Okumura F."/>
<person name="Matsuda M."/>
<person name="Okumura A.J."/>
<person name="Hirata N."/>
<person name="Narita M."/>
<person name="Kohno T."/>
<person name="Yokota J."/>
<person name="Bohgaki M."/>
<person name="Obuse C."/>
<person name="Hatakeyama S."/>
<person name="Obata T."/>
<person name="Noguchi M."/>
</authorList>
<dbReference type="PubMed" id="20059950"/>
<dbReference type="DOI" id="10.1016/j.devcel.2009.09.007"/>
</citation>
<scope>UBIQUITINATION BY TTC3</scope>
<scope>PHOSPHORYLATION AT THR-309 AND SER-474</scope>
<scope>MUTAGENESIS OF THR-309 AND SER-474</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2009" name="Mol. Cell. Biol." volume="29" first="1459" last="1471">
<title>ClipR-59 interacts with Akt and regulates Akt cellular compartmentalization.</title>
<authorList>
<person name="Ding J."/>
<person name="Du K."/>
</authorList>
<dbReference type="PubMed" id="19139280"/>
<dbReference type="DOI" id="10.1128/MCB.00754-08"/>
</citation>
<scope>INTERACTION WITH CLIP3</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2009" name="Sci. Signal." volume="2" first="RA46" last="RA46">
<title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</title>
<authorList>
<person name="Mayya V."/>
<person name="Lundgren D.H."/>
<person name="Hwang S.-I."/>
<person name="Rezaul K."/>
<person name="Wu L."/>
<person name="Eng J.K."/>
<person name="Rodionov V."/>
<person name="Han D.K."/>
</authorList>
<dbReference type="PubMed" id="19690332"/>
<dbReference type="DOI" id="10.1126/scisignal.2000007"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447; THR-451; SER-474 AND SER-478</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Leukemic T-cell</tissue>
</source>
</reference>
<reference key="17">
<citation type="journal article" date="2009" name="Science" volume="325" first="1134" last="1138">
<title>The E3 ligase TRAF6 regulates Akt ubiquitination and activation.</title>
<authorList>
<person name="Yang W.-L."/>
<person name="Wang J."/>
<person name="Chan C.-H."/>
<person name="Lee S.-W."/>
<person name="Campos A.D."/>
<person name="Lamothe B."/>
<person name="Hur L."/>
<person name="Grabiner B.C."/>
<person name="Lin X."/>
<person name="Darnay B.G."/>
<person name="Lin H.-K."/>
</authorList>
<dbReference type="PubMed" id="19713527"/>
<dbReference type="DOI" id="10.1126/science.1175065"/>
</citation>
<scope>UBIQUITINATION</scope>
<scope>INTERACTION WITH TRAF6</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2010" name="Neuro-oncol." volume="12" first="221" last="232">
<title>Akt2 and Akt3 play a pivotal role in malignant gliomas.</title>
<authorList>
<person name="Mure H."/>
<person name="Matsuzaki K."/>
<person name="Kitazato K.T."/>
<person name="Mizobuchi Y."/>
<person name="Kuwayama K."/>
<person name="Kageji T."/>
<person name="Nagahiro S."/>
</authorList>
<dbReference type="PubMed" id="20167810"/>
<dbReference type="DOI" id="10.1093/neuonc/nop026"/>
</citation>
<scope>INVOLVEMENT IN CANCER</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2011" name="Cell. Signal." volume="23" first="1515" last="1527">
<title>Akt signalling in health and disease.</title>
<authorList>
<person name="Hers I."/>
<person name="Vincent E.E."/>
<person name="Tavare J.M."/>
</authorList>
<dbReference type="PubMed" id="21620960"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2011.05.004"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2011" name="Histol. Histopathol." volume="26" first="651" last="662">
<title>Akt1 and Akt2: differentiating the aktion.</title>
<authorList>
<person name="Heron-Milhavet L."/>
<person name="Khouya N."/>
<person name="Fernandez A."/>
<person name="Lamb N.J."/>
</authorList>
<dbReference type="PubMed" id="21432781"/>
<dbReference type="DOI" id="10.14670/HH-26.651"/>
</citation>
<scope>REVIEW ON FUNCTION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2011" name="Mol. Biol. Cell" volume="22" first="2946" last="2956">
<title>Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2).</title>
<authorList>
<person name="Cenni V."/>
<person name="Bavelloni A."/>
<person name="Beretti F."/>
<person name="Tagliavini F."/>
<person name="Manzoli L."/>
<person name="Lattanzi G."/>
<person name="Maraldi N.M."/>
<person name="Cocco L."/>
<person name="Marmiroli S."/>
</authorList>
<dbReference type="PubMed" id="21737686"/>
<dbReference type="DOI" id="10.1091/mbc.E10-11-0928"/>
</citation>
<scope>FUNCTION IN MUSCLE DIFFERENTIATION</scope>
<scope>INTERACTION WITH ANKRD2</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2012" name="Mol. Cell. Proteomics" volume="11" first="M111.015131" last="M111.015131">
<title>Comparative large-scale characterisation of plant vs. mammal proteins reveals similar and idiosyncratic N-alpha acetylation features.</title>
<authorList>
<person name="Bienvenut W.V."/>
<person name="Sumpton D."/>
<person name="Martinez A."/>
<person name="Lilla S."/>
<person name="Espagne C."/>
<person name="Meinnel T."/>
<person name="Giglione C."/>
</authorList>
<dbReference type="PubMed" id="22223895"/>
<dbReference type="DOI" id="10.1074/mcp.M111.015131"/>
</citation>
<scope>ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34 AND SER-126</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="25">
<citation type="journal article" date="2014" name="J. Proteomics" volume="96" first="253" last="262">
<title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.</title>
<authorList>
<person name="Bian Y."/>
<person name="Song C."/>
<person name="Cheng K."/>
<person name="Dong M."/>
<person name="Wang F."/>
<person name="Huang J."/>
<person name="Sun D."/>
<person name="Wang L."/>
<person name="Ye M."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="24275569"/>
<dbReference type="DOI" id="10.1016/j.jprot.2013.11.014"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34 AND THR-451</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Mol. Cell" volume="9" first="1227" last="1240">
<title>Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation.</title>
<authorList>
<person name="Yang J."/>
<person name="Cron P."/>
<person name="Thompson V."/>
<person name="Good V.M."/>
<person name="Hess D."/>
<person name="Hemmings B.A."/>
<person name="Barford D."/>
</authorList>
<dbReference type="PubMed" id="12086620"/>
<dbReference type="DOI" id="10.1016/S1097-2765(02)00550-6"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2002" name="Nat. Struct. Biol." volume="9" first="940" last="944">
<title>Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP.</title>
<authorList>
<person name="Yang J."/>
<person name="Cron P."/>
<person name="Good V.M."/>
<person name="Thompson V."/>
<person name="Hemmings B.A."/>
<person name="Barford D."/>
</authorList>
<dbReference type="PubMed" id="12434148"/>
<dbReference type="DOI" id="10.1038/nsb870"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 146-467 IN COMPLEX WITH PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER AND MANGANESE</scope>
<scope>PHOSPHORYLATION AT THR-309</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2003" name="Structure" volume="11" first="21" last="30">
<title>Crystal structure of an inactive Akt2 kinase domain.</title>
<authorList>
<person name="Huang X."/>
<person name="Begley M."/>
<person name="Morgenstern K.A."/>
<person name="Gu Y."/>
<person name="Rose P."/>
<person name="Zhao H."/>
<person name="Zhu X."/>
</authorList>
<dbReference type="PubMed" id="12517337"/>
<dbReference type="DOI" id="10.1016/S0969-2126(02)00937-1"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 143-481</scope>
<scope>ATP-BINDING</scope>
<scope>SUBSTRATE-BINDING</scope>
<scope>DISULFIDE BOND</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2004" name="J. Biomol. NMR" volume="28" first="137" last="155">
<title>Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates.</title>
<authorList>
<person name="Auguin D."/>
<person name="Barthe P."/>
<person name="Auge-Senegas M.T."/>
<person name="Stern M.H."/>
<person name="Noguchi M."/>
<person name="Roumestand C."/>
</authorList>
<dbReference type="PubMed" id="14755158"/>
<dbReference type="DOI" id="10.1023/B:JNMR.0000013836.62154.c2"/>
</citation>
<scope>STRUCTURE BY NMR OF 1-111</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2007" name="J. Mol. Biol." volume="367" first="882" last="894">
<title>A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.</title>
<authorList>
<person name="Davies T.G."/>
<person name="Verdonk M.L."/>
<person name="Graham B."/>
<person name="Saalau-Bethell S."/>
<person name="Hamlett C.C."/>
<person name="McHardy T."/>
<person name="Collins I."/>
<person name="Garrett M.D."/>
<person name="Workman P."/>
<person name="Woodhead S.J."/>
<person name="Jhoti H."/>
<person name="Barford D."/>
</authorList>
<dbReference type="PubMed" id="17275837"/>
<dbReference type="DOI" id="10.1016/j.jmb.2007.01.004"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 146-467</scope>
<scope>INHIBITOR-BINDING</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2008" name="J. Med. Chem." volume="51" first="5663" last="5679">
<title>Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.</title>
<authorList>
<person name="Heerding D.A."/>
<person name="Rhodes N."/>
<person name="Leber J.D."/>
<person name="Clark T.J."/>
<person name="Keenan R.M."/>
<person name="Lafrance L.V."/>
<person name="Li M."/>
<person name="Safonov I.G."/>
<person name="Takata D.T."/>
<person name="Venslavsky J.W."/>
<person name="Yamashita D.S."/>
<person name="Choudhry A.E."/>
<person name="Copeland R.A."/>
<person name="Lai Z."/>
<person name="Schaber M.D."/>
<person name="Tummino P.J."/>
<person name="Strum S.L."/>
<person name="Wood E.R."/>
<person name="Duckett D.R."/>
<person name="Eberwein D."/>
<person name="Knick V.B."/>
<person name="Lansing T.J."/>
<person name="McConnell R.T."/>
<person name="Zhang S."/>
<person name="Minthorn E.A."/>
<person name="Concha N.O."/>
<person name="Warren G.L."/>
<person name="Kumar R."/>
</authorList>
<dbReference type="PubMed" id="18800763"/>
<dbReference type="DOI" id="10.1021/jm8004527"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 146-480</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="1508" last="1511">
<title>Aminofurazans as potent inhibitors of AKT kinase.</title>
<authorList>
<person name="Rouse M.B."/>
<person name="Seefeld M.A."/>
<person name="Leber J.D."/>
<person name="McNulty K.C."/>
<person name="Sun L."/>
<person name="Miller W.H."/>
<person name="Zhang S."/>
<person name="Minthorn E.A."/>
<person name="Concha N.O."/>
<person name="Choudhry A.E."/>
<person name="Schaber M.D."/>
<person name="Heerding D.A."/>
</authorList>
<dbReference type="PubMed" id="19179070"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2009.01.002"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2004" name="Science" volume="304" first="1325" last="1328">
<title>A family with severe insulin resistance and diabetes due to a mutation in AKT2.</title>
<authorList>
<person name="George S."/>
<person name="Rochford J.J."/>
<person name="Wolfrum C."/>
<person name="Gray S.L."/>
<person name="Schinner S."/>
<person name="Wilson J.C."/>
<person name="Soos M.A."/>
<person name="Murgatroyd P.R."/>
<person name="Williams R.M."/>
<person name="Acerini C.L."/>
<person name="Dunger D.B."/>
<person name="Barford D."/>
<person name="Umpleby A.M."/>
<person name="Wareham N.J."/>
<person name="Davies H.A."/>
<person name="Schafer A.J."/>
<person name="Stoffel M."/>
<person name="O'Rahilly S."/>
<person name="Barroso I."/>
</authorList>
<dbReference type="PubMed" id="15166380"/>
<dbReference type="DOI" id="10.1126/science.1096706"/>
</citation>
<scope>VARIANT NIDDM HIS-274</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] VAL-188 AND LYS-208</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2009" name="J. Clin. Invest." volume="119" first="315" last="322">
<title>Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.</title>
<authorList>
<person name="Semple R.K."/>
<person name="Sleigh A."/>
<person name="Murgatroyd P.R."/>
<person name="Adams C.A."/>
<person name="Bluck L."/>
<person name="Jackson S."/>
<person name="Vottero A."/>
<person name="Kanabar D."/>
<person name="Charlton-Menys V."/>
<person name="Durrington P."/>
<person name="Soos M.A."/>
<person name="Carpenter T.A."/>
<person name="Lomas D.J."/>
<person name="Cochran E.K."/>
<person name="Gorden P."/>
<person name="O'Rahilly S."/>
<person name="Savage D.B."/>
</authorList>
<dbReference type="PubMed" id="19164855"/>
<dbReference type="DOI" id="10.1172/JCI37432"/>
</citation>
<scope>ASSOCIATION OF VARIANT NIDDM HIS-274 WITH TYPICAL METABOLIC DYSLIPIDEMIA</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2011" name="Science" volume="334" first="474" last="474">
<title>An activating mutation of AKT2 and human hypoglycemia.</title>
<authorList>
<person name="Hussain K."/>
<person name="Challis B."/>
<person name="Rocha N."/>
<person name="Payne F."/>
<person name="Minic M."/>
<person name="Thompson A."/>
<person name="Daly A."/>
<person name="Scott C."/>
<person name="Harris J."/>
<person name="Smillie B.J."/>
<person name="Savage D.B."/>
<person name="Ramaswami U."/>
<person name="De Lonlay P."/>
<person name="O'Rahilly S."/>
<person name="Barroso I."/>
<person name="Semple R.K."/>
</authorList>
<dbReference type="PubMed" id="21979934"/>
<dbReference type="DOI" id="10.1126/science.1210878"/>
</citation>
<scope>VARIANT HIHGHH LYS-17</scope>
</reference>
<comment type="function">
<text>AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development.</text>
</comment>
<comment type="function">
<text>One of the few specific substrates of AKT2 identified recently is PITX2. Phosphorylation of PITX2 impairs its association with the CCND1 mRNA-stabilizing complex thus shortening the half-life of CCND1. AKT2 seems also to be the principal isoform responsible of the regulation of glucose uptake. Phosphorylates C2CD5 on 'Ser-197' during insulin-stimulated adipocytes. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. Phosphorylates CLK2 on 'Thr-343'.</text>
</comment>
<comment type="catalytic activity">
<text>ATP + a protein = ADP + a phosphoprotein.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="31 34">Two specific sites, one in the kinase domain (Thr-309) and the other in the C-terminal regulatory region (Ser-474), need to be phosphorylated for its full activation. Aminofurazans are potent AKT2 inhibitors.</text>
</comment>
<comment type="biophysicochemical properties">
<kinetics>
<KM evidence="27">358.4 uM for ATP (for purified and in vitro activated AKT2)</KM>
<KM evidence="27">3.4 uM for peptide substrate (for purified and in vitro activated AKT2)</KM>
<KM evidence="27">564 uM for ATP (for recombinant myristoylated AKT2 expressed and immunoprecipitated from Rat-1 cells)</KM>
<KM evidence="27">2.3 uM for peptide substrate (for recombinant myristoylated AKT2 expressed and immunoprecipitated from Rat-1 cells)</KM>
</kinetics>
</comment>
<comment type="subunit">
<text evidence="18 22 23 28 30 32 35 37">Interacts with BTBD10 (By similarity). Interacts with KCTD20 (By similarity). Interacts (via PH domain) with MTCP1, TCL1A AND TCL1B. Interacts with CLK2, PBH2 and TRAF6. Interacts (when phosphorylated) with CLIP3, the interaction promotes cell membrane localization (PubMed:19139280). Interacts with WDFY2 (via WD repeats 1-3) (PubMed:16792529).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-296058"/>
<interactant intactId="EBI-373586">
<id>P49841</id>
<label>GSK3B</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-296058"/>
<interactant intactId="EBI-352572">
<id>P08238</id>
<label>HSP90AB1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-12562336"/>
<interactant intactId="EBI-12562315">
<id>Q15118-1</id>
<label>PDK1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-296058"/>
<interactant intactId="EBI-741237">
<id>O60504</id>
<label>SORBS3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-296058"/>
<interactant intactId="EBI-353844">
<id>P08670</id>
<label>VIM</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location>Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location>Cell membrane</location>
<topology>Peripheral membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="18">Early endosome</location>
</subcellularLocation>
<text evidence="18">Localizes within both nucleus and cytoplasm of proliferative primary myoblasts and mostly within the nucleus of differentiated primary myoblasts. By virtue of the N-terminal PH domain, is recruited to sites of the plasma membrane containing increased PI(3,4,5)P3 or PI(3,4)P2, cell membrane targeting is also facilitared by interaction with CLIP3. Colocalizes with WDFY2 in early endosomes (By similarity).</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P31751-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P31751-2</id>
<name>2</name>
<sequence type="described" ref="VSP_056930"/>
<text>No experimental confirmation available.</text>
</isoform>
</comment>
<comment type="tissue specificity">
<text>Expressed in all cell types so far analyzed.</text>
</comment>
<comment type="domain">
<text>Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to the plasma membrane.</text>
</comment>
<comment type="PTM">
<text evidence="23 26 36 39">Phosphorylation on Thr-309 and Ser-474 is required for full activity.</text>
</comment>
<comment type="PTM">
<text evidence="35 36">Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT2 ubiquitination. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.</text>
</comment>
<comment type="PTM">
<text evidence="16">O-GlcNAcylation at Thr-306 and Thr-313 inhibits activating phosphorylation at Thr-309 via disrupting the interaction between AKT and PDK1.</text>
</comment>
<comment type="disease">
<text>Defects in AKT2 are a cause of susceptibility to breast cancer (BC). AKT2 promotes metastasis of tumor cells without affecting the latency of tumor development. With AKT3, plays also a pivotal role in the biology of glioblastoma.</text>
</comment>
<comment type="disease" evidence="25 33">
<disease id="DI-02060">
<name>Diabetes mellitus, non-insulin-dependent</name>
<acronym>NIDDM</acronym>
<description>A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.</description>
<dbReference type="MIM" id="125853"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="38">
<disease id="DI-03305">
<name>Hypoinsulinemic hypoglycemia with hemihypertrophy</name>
<acronym>HIHGHH</acronym>
<description>A disorder characterized by hypoglycemia, low insulin levels, low serum levels of ketone bodies and branched-chain amino acids, left-sided hemihypertrophy, neonatal macrosomia, reduced consciousness and hypoglycemic seizures.</description>
<dbReference type="MIM" id="240900"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="41">Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.</text>
</comment>
<comment type="caution">
<text evidence="41">In light of strong homologies in the primary amino acid sequence, the 3 AKT kinases were long surmised to play redundant and overlapping roles. More recent studies has brought into question the redundancy within AKT kinase isoforms and instead pointed to isoform specific functions in different cellular events and diseases. AKT1 is more specifically involved in cellular survival pathways, by inhibiting apoptotic processes; whereas AKT2 is more specific for the insulin receptor signaling pathway. Moreover, while AKT1 and AKT2 are often implicated in many aspects of cellular transformation, the 2 isoforms act in a complementary opposing manner. The role of AKT3 is less clear, though it appears to be predominantly expressed in brain.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/AKT2ID517ch19q13.html"/>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/akt2/"/>
</comment>
<dbReference type="EC" id="2.7.11.1"/>
<dbReference type="EMBL" id="M77198">
<property type="protein sequence ID" value="AAA36585.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M95936">
<property type="protein sequence ID" value="AAA58364.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AK314619">
<property type="protein sequence ID" value="BAG37185.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC118344">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC032709">
<property type="protein sequence ID" value="AAH32709.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC120995">
<property type="protein sequence ID" value="AAI20996.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC120994">
<property type="protein sequence ID" value="AAI20995.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY708392">
<property type="protein sequence ID" value="AAT97984.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS12552.1">
<molecule id="P31751-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS82350.1">
<molecule id="P31751-2"/>
</dbReference>
<dbReference type="PIR" id="A46288">
<property type="entry name" value="A46288"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001317440.1">
<molecule id="P31751-2"/>
<property type="nucleotide sequence ID" value="NM_001330511.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001617.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="NM_001626.5"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011524916.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_011526614.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011524917.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_011526615.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011524918.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_011526616.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011524920.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_011526618.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011524921.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_011526619.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011524922.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_011526620.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016881959.1">
<molecule id="P31751-1"/>
<property type="nucleotide sequence ID" value="XM_017026470.1"/>
</dbReference>
<dbReference type="UniGene" id="Hs.631535"/>
<dbReference type="PDB" id="1GZK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=146-460"/>
</dbReference>
<dbReference type="PDB" id="1GZN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=146-480"/>
</dbReference>
<dbReference type="PDB" id="1GZO">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.75"/>
<property type="chains" value="A=146-460"/>
</dbReference>
<dbReference type="PDB" id="1MRV">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=143-481"/>
</dbReference>
<dbReference type="PDB" id="1MRY">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=143-481"/>
</dbReference>
<dbReference type="PDB" id="1O6K">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.70"/>
<property type="chains" value="A=146-481"/>
</dbReference>
<dbReference type="PDB" id="1O6L">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.60"/>
<property type="chains" value="A=146-467"/>
</dbReference>
<dbReference type="PDB" id="1P6S">
<property type="method" value="NMR"/>
<property type="chains" value="A=1-111"/>
</dbReference>
<dbReference type="PDB" id="2JDO">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A=146-467"/>
</dbReference>
<dbReference type="PDB" id="2JDR">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=146-467"/>
</dbReference>
<dbReference type="PDB" id="2UW9">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=146-467"/>
</dbReference>
<dbReference type="PDB" id="2X39">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.93"/>
<property type="chains" value="A=146-467"/>
</dbReference>
<dbReference type="PDB" id="2XH5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.72"/>
<property type="chains" value="A=146-479"/>
</dbReference>
<dbReference type="PDB" id="3D0E">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A/B=146-480"/>
</dbReference>
<dbReference type="PDB" id="3E87">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A/B=146-480"/>
</dbReference>
<dbReference type="PDB" id="3E88">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/B=146-480"/>
</dbReference>
<dbReference type="PDB" id="3E8D">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A/B=146-480"/>
</dbReference>
<dbReference type="PDBsum" id="1GZK"/>
<dbReference type="PDBsum" id="1GZN"/>
<dbReference type="PDBsum" id="1GZO"/>
<dbReference type="PDBsum" id="1MRV"/>
<dbReference type="PDBsum" id="1MRY"/>
<dbReference type="PDBsum" id="1O6K"/>
<dbReference type="PDBsum" id="1O6L"/>
<dbReference type="PDBsum" id="1P6S"/>
<dbReference type="PDBsum" id="2JDO"/>
<dbReference type="PDBsum" id="2JDR"/>
<dbReference type="PDBsum" id="2UW9"/>
<dbReference type="PDBsum" id="2X39"/>
<dbReference type="PDBsum" id="2XH5"/>
<dbReference type="PDBsum" id="3D0E"/>
<dbReference type="PDBsum" id="3E87"/>
<dbReference type="PDBsum" id="3E88"/>
<dbReference type="PDBsum" id="3E8D"/>
<dbReference type="DisProt" id="DP00304"/>
<dbReference type="ProteinModelPortal" id="P31751"/>
<dbReference type="SMR" id="P31751"/>
<dbReference type="BioGrid" id="106711">
<property type="interactions" value="59"/>
</dbReference>
<dbReference type="CORUM" id="P31751"/>
<dbReference type="DIP" id="DIP-32583N"/>
<dbReference type="ELM" id="P31751"/>
<dbReference type="IntAct" id="P31751">
<property type="interactions" value="33"/>
</dbReference>
<dbReference type="MINT" id="MINT-87790"/>
<dbReference type="STRING" id="9606.ENSP00000375892"/>
<dbReference type="BindingDB" id="P31751"/>
<dbReference type="ChEMBL" id="CHEMBL2431"/>
<dbReference type="DrugBank" id="DB08073">
<property type="generic name" value="(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE"/>
</dbReference>
<dbReference type="DrugBank" id="DB07859">
<property type="generic name" value="4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE"/>
</dbReference>
<dbReference type="DrugBank" id="DB07947">
<property type="generic name" value="ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1480"/>
<dbReference type="iPTMnet" id="P31751"/>
<dbReference type="PhosphoSitePlus" id="P31751"/>
<dbReference type="BioMuta" id="AKT2"/>
<dbReference type="DMDM" id="1170703"/>
<dbReference type="EPD" id="P31751"/>
<dbReference type="MaxQB" id="P31751"/>
<dbReference type="PaxDb" id="P31751"/>
<dbReference type="PeptideAtlas" id="P31751"/>
<dbReference type="PRIDE" id="P31751"/>
<dbReference type="DNASU" id="208"/>
<dbReference type="Ensembl" id="ENST00000311278">
<molecule id="P31751-2"/>
<property type="protein sequence ID" value="ENSP00000309428"/>
<property type="gene ID" value="ENSG00000105221"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000392038">
<molecule id="P31751-1"/>
<property type="protein sequence ID" value="ENSP00000375892"/>
<property type="gene ID" value="ENSG00000105221"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000424901">
<molecule id="P31751-2"/>
<property type="protein sequence ID" value="ENSP00000399532"/>
<property type="gene ID" value="ENSG00000105221"/>
</dbReference>
<dbReference type="GeneID" id="208"/>
<dbReference type="KEGG" id="hsa:208"/>
<dbReference type="UCSC" id="uc002onf.3">
<molecule id="P31751-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="208"/>
<dbReference type="DisGeNET" id="208"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000105221.16"/>
<dbReference type="GeneCards" id="AKT2"/>
<dbReference type="HGNC" id="HGNC:392">
<property type="gene designation" value="AKT2"/>
</dbReference>
<dbReference type="HPA" id="CAB004204"/>
<dbReference type="HPA" id="HPA064521"/>
<dbReference type="MalaCards" id="AKT2"/>
<dbReference type="MIM" id="125853">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="164731">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="240900">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P31751"/>
<dbReference type="OpenTargets" id="ENSG00000105221"/>
<dbReference type="Orphanet" id="79085">
<property type="disease" value="Familial partial lipodystrophy due to AKT2 mutations"/>
</dbReference>
<dbReference type="Orphanet" id="293964">
<property type="disease" value="Hypoinsulinemic hypoglycemia and body hemihypertrophy"/>
</dbReference>
<dbReference type="PharmGKB" id="PA24685"/>
<dbReference type="eggNOG" id="KOG0598">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="ENOG410XNPH">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00890000139324"/>
<dbReference type="HOGENOM" id="HOG000233033"/>
<dbReference type="HOVERGEN" id="HBG108317"/>
<dbReference type="InParanoid" id="P31751"/>
<dbReference type="KO" id="K04456"/>
<dbReference type="OrthoDB" id="EOG091G06FF"/>
<dbReference type="PhylomeDB" id="P31751"/>
<dbReference type="TreeFam" id="TF102004"/>
<dbReference type="BRENDA" id="2.7.11.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-111447">
<property type="pathway name" value="Activation of BAD and translocation to mitochondria"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-114604">
<property type="pathway name" value="GPVI-mediated activation cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1257604">
<property type="pathway name" value="PIP3 activates AKT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1358803">
<property type="pathway name" value="Downregulation of ERBB2:ERBB3 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1445148">
<property type="pathway name" value="Translocation of GLUT4 to the plasma membrane"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-165158">
<property type="pathway name" value="Activation of AKT2"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-165160">
<property type="pathway name" value="PDE3B signalling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-165181">
<property type="pathway name" value="Inhibition of TSC complex formation by PKB"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-198323">
<property type="pathway name" value="AKT phosphorylates targets in the cytosol"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-198693">
<property type="pathway name" value="AKT phosphorylates targets in the nucleus"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-199418">
<property type="pathway name" value="Negative regulation of the PI3K/AKT network"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-211163">
<property type="pathway name" value="AKT-mediated inactivation of FOXO1A"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3769402">
<property type="pathway name" value="Deactivation of the beta-catenin transactivating complex"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-389357">
<property type="pathway name" value="CD28 dependent PI3K/Akt signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-389513">
<property type="pathway name" value="CTLA4 inhibitory signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-392451">
<property type="pathway name" value="G beta:gamma signalling through PI3Kgamma"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5218920">
<property type="pathway name" value="VEGFR2 mediated vascular permeability"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5628897">
<property type="pathway name" value="TP53 Regulates Metabolic Genes"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5674400">
<property type="pathway name" value="Constitutive Signaling by AKT1 E17K in Cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6804757">
<property type="pathway name" value="Regulation of TP53 Degradation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6804758">
<property type="pathway name" value="Regulation of TP53 Activity through Acetylation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6804759">
<property type="pathway name" value="Regulation of TP53 Activity through Association with Co-factors"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-69202">
<property type="pathway name" value="Cyclin E associated events during G1/S transition"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8876198">
<property type="pathway name" value="RAB GEFs exchange GTP for GDP on RABs"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8941332">
<property type="pathway name" value="RUNX2 regulates genes involved in cell migration"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8948751">
<property type="pathway name" value="Regulation of PTEN stability and activity"/>
</dbReference>
<dbReference type="SABIO-RK" id="P31751"/>
<dbReference type="SignaLink" id="P31751"/>
<dbReference type="SIGNOR" id="P31751"/>
<dbReference type="ChiTaRS" id="AKT2">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P31751"/>
<dbReference type="GeneWiki" id="AKT2"/>
<dbReference type="GenomeRNAi" id="208"/>
<dbReference type="PRO" id="PR:P31751"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 19"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000105221"/>
<dbReference type="CleanEx" id="HS_AKT2"/>
<dbReference type="ExpressionAtlas" id="P31751">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P31751">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005938">
<property type="term" value="C:cell cortex"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005769">
<property type="term" value="C:early endosome"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0043231">
<property type="term" value="C:intracellular membrane-bounded organelle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005654">
<property type="term" value="C:nucleoplasm"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043234">
<property type="term" value="C:protein complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032587">
<property type="term" value="C:ruffle membrane"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046872">
<property type="term" value="F:metal ion binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0004674">
<property type="term" value="F:protein serine/threonine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0090630">
<property type="term" value="P:activation of GTPase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0008643">
<property type="term" value="P:carbohydrate transport"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0006464">
<property type="term" value="P:cellular protein modification process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0071486">
<property type="term" value="P:cellular response to high light intensity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032869">
<property type="term" value="P:cellular response to insulin stimulus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045444">
<property type="term" value="P:fat cell differentiation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006006">
<property type="term" value="P:glucose metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0005978">
<property type="term" value="P:glycogen biosynthetic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0008286">
<property type="term" value="P:insulin receptor signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0065002">
<property type="term" value="P:intracellular protein transmembrane transport"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035556">
<property type="term" value="P:intracellular signal transduction"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0060644">
<property type="term" value="P:mammary gland epithelial cell differentiation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010748">
<property type="term" value="P:negative regulation of plasma membrane long-chain fatty acid transport"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0018105">
<property type="term" value="P:peptidyl-serine phosphorylation"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0032287">
<property type="term" value="P:peripheral nervous system myelin maintenance"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0030335">
<property type="term" value="P:positive regulation of cell migration"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:2000147">
<property type="term" value="P:positive regulation of cell motility"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032000">
<property type="term" value="P:positive regulation of fatty acid beta-oxidation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046326">
<property type="term" value="P:positive regulation of glucose import"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:2001275">
<property type="term" value="P:positive regulation of glucose import in response to insulin stimulus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010907">
<property type="term" value="P:positive regulation of glucose metabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045725">
<property type="term" value="P:positive regulation of glycogen biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010918">
<property type="term" value="P:positive regulation of mitochondrial membrane potential"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001934">
<property type="term" value="P:positive regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0090314">
<property type="term" value="P:positive regulation of protein targeting to membrane"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031340">
<property type="term" value="P:positive regulation of vesicle fusion"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0072659">
<property type="term" value="P:protein localization to plasma membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0071156">
<property type="term" value="P:regulation of cell cycle arrest"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030334">
<property type="term" value="P:regulation of cell migration"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006417">
<property type="term" value="P:regulation of translation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0097473">
<property type="term" value="P:retinal rod cell apoptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007165">
<property type="term" value="P:signal transduction"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="CDD" id="cd05595">
<property type="entry name" value="STKc_PKB_beta"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="2.30.29.30">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR000961">
<property type="entry name" value="AGC-kinase_C"/>
</dbReference>
<dbReference type="InterPro" id="IPR034677">
<property type="entry name" value="Akt2"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR011993">
<property type="entry name" value="PH-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR001849">
<property type="entry name" value="PH_domain"/>
</dbReference>
<dbReference type="InterPro" id="IPR017892">
<property type="entry name" value="Pkinase_C"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR008271">
<property type="entry name" value="Ser/Thr_kinase_AS"/>
</dbReference>
<dbReference type="Pfam" id="PF00169">
<property type="entry name" value="PH"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00069">
<property type="entry name" value="Pkinase"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00433">
<property type="entry name" value="Pkinase_C"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00233">
<property type="entry name" value="PH"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00133">
<property type="entry name" value="S_TK_X"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00220">
<property type="entry name" value="S_TKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF50729">
<property type="entry name" value="SSF50729"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS51285">
<property type="entry name" value="AGC_KINASE_CTER"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50003">
<property type="entry name" value="PH_DOMAIN"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00108">
<property type="entry name" value="PROTEIN_KINASE_ST"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0007">Acetylation</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0053">Apoptosis</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-0119">Carbohydrate metabolism</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0217">Developmental protein</keyword>
<keyword id="KW-0219">Diabetes mellitus</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0967">Endosome</keyword>
<keyword id="KW-0313">Glucose metabolism</keyword>
<keyword id="KW-0320">Glycogen biosynthesis</keyword>
<keyword id="KW-0321">Glycogen metabolism</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0464">Manganese</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0656">Proto-oncogene</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0723">Serine/threonine-protein kinase</keyword>
<keyword id="KW-0762">Sugar transport</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0810">Translation regulation</keyword>
<keyword id="KW-0813">Transport</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="chain" description="RAC-beta serine/threonine-protein kinase" id="PRO_0000085608">
<location>
<begin position="1"/>
<end position="481"/>
</location>
</feature>
<feature type="domain" description="PH" evidence="19">
<location>
<begin position="5"/>
<end position="108"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="20">
<location>
<begin position="152"/>
<end position="409"/>
</location>
</feature>
<feature type="domain" description="AGC-kinase C-terminal">
<location>
<begin position="410"/>
<end position="481"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="20">
<location>
<begin position="158"/>
<end position="166"/>
</location>
</feature>
<feature type="region of interest" description="Inhibitor binding">
<location>
<begin position="230"/>
<end position="232"/>
</location>
</feature>
<feature type="region of interest" description="Inhibitor binding">
<location>
<begin position="277"/>
<end position="279"/>
</location>
</feature>
<feature type="region of interest" description="Inhibitor binding">
<location>
<begin position="292"/>
<end position="293"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="20 21">
<location>
<position position="275"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Manganese" evidence="23">
<location>
<position position="280"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Manganese" evidence="23">
<location>
<position position="293"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="20">
<location>
<position position="181"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor">
<location>
<position position="181"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor">
<location>
<position position="200"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor; via amide nitrogen">
<location>
<position position="232"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor">
<location>
<position position="236"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor; via carbonyl oxygen">
<location>
<position position="279"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor">
<location>
<position position="293"/>
</location>
</feature>
<feature type="binding site" description="Inhibitor; via amide nitrogen">
<location>
<position position="294"/>
</location>
</feature>
<feature type="modified residue" description="N-acetylmethionine" evidence="13">
<location>
<position position="1"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine" evidence="17">
<location>
<position position="14"/>
</location>
</feature>
<feature type="modified residue" description="N6-acetyllysine" evidence="17">
<location>
<position position="20"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="14 15">
<location>
<position position="34"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="11 14">
<location>
<position position="126"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; alternate" evidence="17">
<location>
<position position="128"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; alternate" evidence="17">
<location>
<position position="131"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="17">
<location>
<position position="178"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine; by PDPK1" evidence="23 26 36 39">
<location>
<position position="309"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="12">
<location>
<position position="447"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="17">
<location>
<position position="449"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="12 15">
<location>
<position position="451"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="12 26 36">
<location>
<position position="474"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="17">
<location>
<position position="475"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="12">
<location>
<position position="478"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine; alternate" evidence="16">
<location>
<position position="128"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) serine; alternate" evidence="16">
<location>
<position position="131"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) threonine" evidence="16">
<location>
<position position="306"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GlcNAc) threonine" evidence="16">
<location>
<position position="313"/>
</location>
</feature>
<feature type="disulfide bond" evidence="16">
<location>
<begin position="60"/>
<end position="77"/>
</location>
</feature>
<feature type="disulfide bond" evidence="24">
<location>
<begin position="297"/>
<end position="311"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" evidence="17">
<location>
<position position="285"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_056930" evidence="40">
<location>
<begin position="278"/>
<end position="320"/>
</location>
</feature>
<feature type="sequence variant" description="In HIHGHH; exhibits plasma membrane localization in serum-starved cells and produced inappropriate tonic nuclear exclusion of FOXO1 in preadipocytes; dbSNP:rs387906659." id="VAR_067309" evidence="38">
<original>E</original>
<variation>K</variation>
<location>
<position position="17"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55859611." id="VAR_040356" evidence="29">
<original>I</original>
<variation>V</variation>
<location>
<position position="188"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35817154." id="VAR_040357" evidence="29">
<original>R</original>
<variation>K</variation>
<location>
<position position="208"/>
</location>
</feature>
<feature type="sequence variant" description="In NIDDM; associated with typical metabolic dyslipidemia with elevated fastin triglyceride, high VLDL triglyceride/cholesterol ratios, low HDL cholesterol levels and high small dense LDL levels; de novo lipogenesis and liver fat are also significantly elevated in this subject; dbSNP:rs121434593." id="VAR_067310" evidence="25">
<original>R</original>
<variation>H</variation>
<location>
<position position="274"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs interaction with TTC3; when associated with A-474." evidence="26 36">
<original>T</original>
<variation>A</variation>
<location>
<position position="309"/>
</location>
</feature>
<feature type="mutagenesis site" description="Constitutively active; when associated with D-474." evidence="26 36">
<original>T</original>
<variation>E</variation>
<location>
<position position="309"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impairs interaction with TTC3; when associated with A-309." evidence="26 36">
<original>S</original>
<variation>A</variation>
<location>
<position position="474"/>
</location>
</feature>
<feature type="mutagenesis site" description="Constitutively active; when associated with E-309." evidence="26 36">
<original>S</original>
<variation>D</variation>
<location>
<position position="474"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA36585." ref="1" evidence="41">
<original>SIRE</original>
<variation>FREEKDLLMSLFVSLILFSDFSSLKSHSFSSNFILLSFSSLKK</variation>
<location>
<begin position="478"/>
<end position="481"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="6"/>
<end position="15"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="17"/>
<end position="20"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="22"/>
<end position="30"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="31"/>
<end position="33"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="34"/>
<end position="40"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="45"/>
<end position="47"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="52"/>
<end position="56"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="58"/>
<end position="60"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="62"/>
<end position="65"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="67"/>
<end position="75"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="86"/>
<end position="92"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="93"/>
<end position="110"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="149"/>
<end position="151"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="152"/>
<end position="160"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="162"/>
<end position="171"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="172"/>
<end position="174"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="177"/>
<end position="184"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="185"/>
<end position="190"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="194"/>
<end position="205"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="215"/>
<end position="220"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="222"/>
<end position="230"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="237"/>
<end position="244"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="249"/>
<end position="268"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="280"/>
<end position="283"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="289"/>
<end position="291"/>
</location>
</feature>
<feature type="strand" evidence="8">
<location>
<begin position="298"/>
<end position="300"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="310"/>
<end position="312"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="314"/>
<end position="316"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="319"/>
<end position="322"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="323"/>
<end position="325"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="331"/>
<end position="345"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="351"/>
<end position="353"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="355"/>
<end position="364"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="371"/>
<end position="373"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="375"/>
<end position="384"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="389"/>
<end position="391"/>
</location>
</feature>
<feature type="turn" evidence="9">
<location>
<begin position="393"/>
<end position="395"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="397"/>
<end position="399"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="400"/>
<end position="404"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="407"/>
<end position="409"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="414"/>
<end position="418"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="431"/>
<end position="434"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="437"/>
<end position="439"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="441"/>
<end position="444"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="470"/>
<end position="472"/>
</location>
</feature>
<feature type="strand" evidence="10">
<location>
<begin position="474"/>
<end position="476"/>
</location>
</feature>
<feature type="turn" evidence="10">
<location>
<begin position="477"/>
<end position="479"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1GZK"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1GZN"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1GZO"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1O6L"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1P6S"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2JDO"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2JDR"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2UW9"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2X39"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3D0E"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="19690332"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="22223895"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="24275569"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000250"/>
<evidence key="17" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P31749"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q60823"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00145"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10027"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10983986"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12434148"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12517337"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15166380"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15890450"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16540465"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16792529"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17565718"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18800763"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19139280"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19164855"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19179070"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19713527"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20059950"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21737686"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21979934"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9512493"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000305"/>
<sequence length="481" mass="55769" checksum="B18C87A7246BFB24" modified="1995-11-01" version="2">
MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAEC
QLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPM
DYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAM
KILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFH
LSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKITDFGLCKEG
ISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLFE
LILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQK
KLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIR
E
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>